Microdosing MDMA for Health & Longevity - Quick Reference Sheet

Microdosing MDMA for Health & Longevity

Created on 09/30/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

MDMA, a synthetic compound sold illicitly as ecstasy or molly, is microdosed in small repeated amounts for subtle shifts in mood, social ease or pain. No benefit rises above low confidence; documented effects come almost entirely from full doses with psychotherapy. The firmest risk is a short-lived rise in blood pressure, heart rate and body temperature; heart-valve concerns are uncertain at small doses, and illicit supply is often mislabeled. (Full Review)

Protocol

Clinical case regimen
12.5–25 mg every other day
No established protocol; one supervised case, four months, echocardiography before and after
Community microdosing convention
About 8–15 mg, then two days off
About one-tenth of a full dose; untested for MDMA
Time of day
Morning
Places the 1–3 hour peak in daytime; most of the drug clears before sleep
Time to effect
Chronic pain relief
Weeks
Single case; no study defines time to benefit
Acute effects onset
Within about 45 minutes
Acute effects begin after oral intake
Peak
1–3 hours
Half-life about 8 hours

Benefits

Contraindications
  • Pregnant or breastfeeding people
  • People under 18 years
  • Uncontrolled hypertension (≥140/90 mmHg at rest)
  • Known heart-valve disease (mild-to-moderate or greater regurgitation), pulmonary hypertension, or valve findings after fenfluramine or ergot-derived drugs (older migraine and Parkinson's medications such as pergolide)
  • Coronary artery disease, heart failure (ejection fraction <40%), stroke or heart attack within the past 6 months, or arrhythmias (atrial fibrillation, Wolff-Parkinson-White syndrome)
  • Personal or first-degree family history of psychosis or bipolar I disorder
  • Current MAOI use (phenelzine, tranylcypromine, moclobemide, selegiline, linezolid), or within the drug-specific washout (at least 14 days for irreversible MAOIs)
  • Harmala-containing products (Syrian rue, ayahuasca)
  • Strong enzyme-inhibiting boosters (ritonavir, cobicistat)
  • Serum sodium <135 mmol/L or conditions causing low sodium
  • Liver cirrhosis (Child-Pugh class B or C) or liver enzymes >2.5 times the upper normal limit
  • Severe kidney disease (eGFR <30 mL/min/1.73 m²)
  • Current or past stimulant use disorder
  • People subject to occupational drug testing or legal supervision
Key Interactions
  • SSRIs and SNRIs (sertraline, fluoxetine, paroxetine, citalopram, duloxetine, venlafaxine)
  • Bupropion
  • CYP2D6-dependent drugs (metoprolol, codeine, tramadol, tamoxifen, dextromethorphan)
  • Prescription stimulants (amphetamine, methylphenidate)
  • Dextromethorphan cough products
  • Decongestants (pseudoephedrine, phenylephrine)
  • Alcohol
  • Serotonergic supplements (St John's wort, 5-HTP, L-tryptophan, SAMe)
  • Stimulant supplements (high-dose caffeine, yohimbine, synephrine)
  • Sauna, hot baths and hot-environment exercise
  • Other psychedelics (lysergic acid diethylamide, psilocybin)

Risk & Side Effects

  • High: Acute cardiovascular and body-temperature rise
  • Medium: Misrepresented illicit supply
  • Low: Heart-valve damage, serotonin-system changes and memory, low blood sodium, mid-week low mood, sleep disruption, habit formation, serotonin toxicity, psychiatric destabilization, liver injury
  • Speculative: Dopamine-neuron loss after adolescent exposure, pulmonary hypertension

Monitoring

Marker Target Why
Blood pressure (seated) <120/80 mmHg at rest; systolic <140 mmHg 60–120 min post-dose Acute stimulant load
Resting heart rate 50–70 beats/min Acute stimulant load
Echocardiogram No more than trace valve regurgitation; normal leaflet thickness Detects 5-HT2B valve damage
NT-proBNP <125 pg/mL Early heart-strain signal
Serum sodium 138–142 mmol/L Hyponatremia risk
ALT 10–25 U/L Liver injury
eGFR ≥90 mL/min/1.73 m² Kidney clearance and fluid handling
CYP2D6 genotype Normal metabolizer Predicts MDMA accumulation
PHQ-9 score 0–4 Tracks low mood

Cadence: Baseline before the first dose; blood pressure and heart rate 60–120 minutes after each of the first three doses, then weekly; serum sodium and liver enzymes at 4 weeks; depression questionnaire every 2 weeks; echocardiogram at 3 months, every 6–12 months if dosing continues, and once after the course ends

Qualitative Assessment

  • Sleep latency and sleep quality on dosing versus non-dosing days
  • Mood stability, including any dip 2–4 days after doses
  • Ease in social interactions and sense of connection
  • Daily pain rating on a 0–10 scale, where pain is the target
  • Jaw tension, teeth grinding, appetite and body temperature on dosing days
  • Cravings, urges to increase dose, or dosing outside the planned schedule